← Back to Clinical Trials
Recruiting NCT07576270

NCT07576270 Effect of Resisted Deep Breathing and Myofascial Release in Postmastectomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07576270
Status Recruiting
Phase
Sponsor Riphah International University
Condition Post Mastectomy Lymphedema
Study Type INTERVENTIONAL
Enrollment 48 participants
Start Date 2025-10-01
Primary Completion 2026-06-01

Eligibility & Interventions

Sex Female only
Min Age 45 Years
Max Age 64 Years
Study Type INTERVENTIONAL
Interventions
Resisted Deep BreathingMyofascial release

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 48 participants in total. It began in 2025-10-01 with a primary completion date of 2026-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to determine the combined effect of resisted deep breathing and Myofascial release on pain, respiratory efficiency, chest mobility and lymph edema in Postmastectomy.

Eligibility Criteria

Inclusion Criteria: * Radiation therapy and chemotherapy was finished at least three months * 6 months after mastectomy for breast cancer being diagnosed without lymphedema or with stage 1 lymphedema * Complete unilateral Mastectomy * pain and having one or more of the following symptoms: heaviness, numbness, oppression, stiffness, alterations in the function, or mobility of the limited shoulder range of motion. Exclusion Criteria: * Presence of shoulder pathologies for which surgical indications exist * Musculoskeletal injury in adjacent areas (shoulder or neck etc.) * bilateral surgery for the treatment of breast cancer * Bilateral lymphadenectomy * Open wounds on upper limbs * Circulatory disorders * History of shoulder surgery for reasons other than breast cancer.

Contact & Investigator

Central Contact

imran amjad

✉ imran.amjad@riphah.edu.pk

📞 03324390125

Principal Investigator

hina gul, PhD*

PRINCIPAL INVESTIGATOR

Riphah International University

Frequently Asked Questions

Who can join the NCT07576270 clinical trial?

This trial is open to female participants only, aged 45 Years or older, up to 64 Years, studying Post Mastectomy Lymphedema. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07576270 currently recruiting?

Yes, NCT07576270 is actively recruiting participants. Contact the research team at imran.amjad@riphah.edu.pk for enrollment information.

Where is the NCT07576270 trial being conducted?

This trial is being conducted at Lahore, Pakistan.

Who is sponsoring the NCT07576270 clinical trial?

NCT07576270 is sponsored by Riphah International University. The principal investigator is hina gul, PhD* at Riphah International University. The trial plans to enroll 48 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology